Discovery and pharmacology of varenicline: An a4b2 nAChR partial agonist for smoking cessation

被引：0
|
作者：
Rollema, H. [1 ]
Coe, J. W. [1 ]
机构：
[1] Pfizer Inc, Global Res & Dev, Groton Labs, Groton, CT 06340 USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2006年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S55 / S55
页数：1
相关论文
共 50 条
  • [21] The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data
    Hans Rollema
    Raymond S. Hurst
    Psychopharmacology, 2018, 235 : 2479 - 2505
  • [22] The partial NACHR agonist varenicline for the treatment of alcoholism?: Pre-clinical biochemical data
    Lof, E.
    Ericson, M.
    Stomberg, R.
    Soderpalm, B.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2008, 32 (06) : 84A - 84A
  • [23] Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation
    Rollema, Hans
    Coe, Jotham W.
    Chambers, Leslie K.
    Hurst, Raymond S.
    Stahl, Stephen M.
    Williams, Kathryn E.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2007, 28 (07) : 316 - 325
  • [24] Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation -: A randomized controlled trial
    Jorenby, Douglas E.
    Hays, J. Taylor
    Rigotti, Nancy A.
    Azoulay, Salomon
    Watsky, Eric J.
    Williams, Kathryn E.
    Billing, Clare B.
    Gong, Jason
    Reeves, Karen R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (01): : 56 - 63
  • [25] A randomized, placebo-controlled trial of varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers
    Tsai, Shih-Tzu
    Cho, Hong-Jun
    Cheng, Huey-Shinn
    Kim, Cheol-Hwan
    Hsueh, Kuang-Chieh
    Billing, Clare B., Jr.
    Williams, Kathryn E.
    CLINICAL THERAPEUTICS, 2007, 29 (06) : 1027 - 1039
  • [26] Partial agonism at nicotinic receptors with varenicline - a new approach to smoking cessation
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (18) : 2599 - 2603
  • [27] Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors
    Mihalak, Karla B.
    Carroll, F. Ivy
    Luetje, Charles W.
    MOLECULAR PHARMACOLOGY, 2006, 70 (03) : 801 - 805
  • [28] EFFICACY OF VARENICLINE, AN NICOTINIC ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, VS PLACEBO FOR SMOKING CESSATION. A RANDOMIZED CONTROLLED TRIAL
    Wiratmoko, Mirsyam R.
    Yunus, Faisal
    Susanto, Agus D.
    Ginting, Tribowo T.
    Kekalih, Aria
    RESPIROLOGY, 2013, 18 : 66 - 66
  • [29] Effects of the Nicotinic Partial Agonist Varenicline on Smoking Lapse Behaviour in Schizophrenia
    Kozak, Karolina
    Dermody, Sarah S.
    Sharif-Razi, Maryam
    Coles, Alexandria S.
    Morozova, Marya
    Wing, Victoria C.
    McKee, Sherry A.
    George, Tony P.
    CANADIAN JOURNAL OF ADDICTION, 2019, 10 (02) : 27 - 35
  • [30] Discovery and development of varenicline for smoking cessation (vol 28, pg 1, 2018)
    Jordan, C. J.
    Xi, Z. X.
    EXPERT OPINION ON DRUG DISCOVERY, 2018, 13 (07) : IX - XI
12345